|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
103,650,000 |
Market
Cap: |
1.71(B) |
Last
Volume: |
1,107,565 |
Avg
Vol: |
1,681,610 |
52
Week Range: |
$11.5 - $17.29 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 604 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Catalyst Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing medicines for patients living with rare diseases. Co.'s primary product, Firdapse®, is used for the treatment of adult patients (ages 17 and above) with Lambert-Eaton, Myasthenic Syndrome, a rare autoimmune neuromuscular disorder characterized by muscle weakness of the limbs. Co. has developed its vigabatrin (CPP-109) as a generic version of Sabril®. Co. has an agreement with Endo International plc's subsidiary, Endo Ventures Limited, for the development and commercialization of generic Sabril® tablets through Endo's U.S. Generic Pharmaceuticals segment, Par Pharmaceutical.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
50,000 |
304,000 |
304,000 |
4,223,516 |
Total Sell Value |
$803,000 |
$4,338,050 |
$4,338,050 |
$62,649,148 |
Total People Sold |
2 |
6 |
6 |
12 |
Total Sell Transactions |
2 |
8 |
8 |
53 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Miller Steve |
Chief Operating Officer |
|
2017-11-06 |
4 |
OE |
$0.47 |
$94,000 |
D/D |
200,000 |
657,687 |
|
- |
|
Mcenany Patrick J |
President and CEO |
|
2017-11-06 |
4 |
OE |
$0.47 |
$94,000 |
D/D |
200,000 |
4,671,026 |
|
- |
|
Mcenany Patrick J |
President and CEO |
|
2017-09-05 |
4 |
B |
$2.58 |
$51,560 |
D/D |
20,000 |
4,471,026 |
2.81 |
- |
|
Mcenany Patrick J |
President and CEO |
|
2017-05-22 |
4 |
OE |
$1.04 |
$32,500 |
D/D |
31,250 |
4,451,026 |
|
- |
|
O'keeffe Charles B |
Director |
|
2017-05-11 |
4 |
OE |
$1.04 |
$32,500 |
D/D |
31,250 |
463,376 |
|
- |
|
Mcenany Patrick J |
President and CEO |
|
2016-11-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,667 |
4,419,776 |
|
- |
|
O'keeffe Charles B |
Director |
|
2016-07-12 |
4 |
B |
$0.81 |
$16,272 |
D/D |
20,000 |
432,126 |
2.39 |
- |
|
Coelho Philip H |
Director |
|
2016-06-17 |
4 |
B |
$0.75 |
$11,383 |
D/D |
15,000 |
173,287 |
2.39 |
- |
|
Denkhaus Donald A |
Director |
|
2016-06-14 |
4 |
B |
$0.65 |
$32,500 |
D/D |
50,000 |
100,000 |
2.39 |
- |
|
Mcenany Patrick J |
President and CEO |
|
2016-06-14 |
4 |
B |
$0.65 |
$68,529 |
D/D |
105,300 |
4,393,109 |
2.81 |
- |
|
O'keeffe Charles B |
Director |
|
2016-04-26 |
4 |
B |
$0.60 |
$11,920 |
D/D |
20,000 |
412,126 |
2.39 |
- |
|
Mcenany Patrick J |
President and CEO |
|
2016-04-26 |
4 |
B |
$0.65 |
$32,430 |
D/D |
50,000 |
4,287,809 |
2.81 |
- |
|
Coelho Philip H |
Director |
|
2016-03-17 |
4 |
B |
$1.06 |
$10,600 |
D/D |
10,000 |
158,287 |
2.39 |
- |
|
O'keeffe Charles B |
Director |
|
2016-03-16 |
4 |
B |
$1.11 |
$11,062 |
D/D |
10,000 |
392,126 |
2.39 |
- |
|
Miller Steve |
Chief Operating Officer |
|
2016-01-11 |
4 |
B |
$1.80 |
$14,279 |
D/D |
7,933 |
457,687 |
2.74 |
- |
|
O'keeffe Charles B |
Director |
|
2016-01-08 |
4 |
B |
$1.94 |
$9,685 |
D/D |
5,000 |
377,126 |
2.39 |
- |
|
Denkhaus Donald A |
Director |
|
2016-01-07 |
4 |
B |
$2.03 |
$50,750 |
D/D |
25,000 |
50,000 |
2.39 |
- |
|
Mcenany Patrick J |
President and CEO |
|
2015-12-28 |
4 |
B |
$2.39 |
$59,725 |
D/D |
25,000 |
4,237,809 |
2.81 |
- |
|
O'keeffe Charles B |
Director |
|
2015-12-23 |
4 |
B |
$2.41 |
$12,044 |
D/D |
5,000 |
372,126 |
2.39 |
- |
|
Mcenany Patrick J |
President and CEO |
|
2015-12-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,666 |
4,212,809 |
|
- |
|
O'keeffe Charles B |
Director |
|
2015-11-19 |
4 |
B |
$2.30 |
$11,482 |
D/D |
5,000 |
367,126 |
2.39 |
- |
|
Winship M Douglas |
VP, Regulatory Operations |
|
2015-11-04 |
4 |
OE |
$1.09 |
$65,400 |
D/D |
60,000 |
134,131 |
|
- |
|
Mcenany Patrick J |
President and CEO |
|
2015-10-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(26,119) |
4,186,143 |
|
- |
|
Mcenany Patrick J |
President and CEO |
|
2015-10-29 |
4 |
OE |
$1.09 |
$81,750 |
D/D |
75,000 |
4,212,262 |
|
- |
|
Tierney David S |
Director |
|
2015-10-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(10,000) |
263,401 |
|
- |
|
434 Records found
|
|
Page 11 of 18 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|